The role of FOLFOXIRI in chemorefractory metastatic colorectal cancer patients
Introduction: The use of FOLFOXIRI (oxaliplatin, irinotecan, leucovorin, and 5-fluorouracil) as first-line therapy for metastatic colorectal cancer (mCRC) is well-established. However, there is no data about the effectiveness of this regimen in pretreated patients in the current literature. In this...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Turkiye Klinikleri
2018-04-01
|
| Series: | Journal of Oncological Sciences |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2452336417301310 |
| _version_ | 1797921982244716544 |
|---|---|
| author | Ibrahim Yildiz Halil Taskaynatan Umut Varol Tarik Salman Utku Oflazoglu Yasar Yildiz Yuksel Kucukzeybek Ahmet Alacacioglu Mustafa Oktay Tarhan |
| author_facet | Ibrahim Yildiz Halil Taskaynatan Umut Varol Tarik Salman Utku Oflazoglu Yasar Yildiz Yuksel Kucukzeybek Ahmet Alacacioglu Mustafa Oktay Tarhan |
| author_sort | Ibrahim Yildiz |
| collection | DOAJ |
| description | Introduction: The use of FOLFOXIRI (oxaliplatin, irinotecan, leucovorin, and 5-fluorouracil) as first-line therapy for metastatic colorectal cancer (mCRC) is well-established. However, there is no data about the effectiveness of this regimen in pretreated patients in the current literature. In this case report, we aim to evaluate the efficacy and benefit of FOLFOXIRI in patients who received standard regimens. Case report: 3 patients were treated with FOLFOXIRI and 1 patient received FOLFOXIRI + bevasizumab. Three patients had a partial response to FOLFOXIRI; one of these patients showed disease progression on this chemotherapy regimen and died. Progression free survival (PFS) of three patients was 5.5, 9 and 7.5 months respectively. One patient showed progression without any response to treatment. Conclusion: We observed a partial response in 3 patients who were treated with FOLFOXİRİ and their progression-free survival was more than 3 months. These patients were treated with FOLFOXİRİ as a third or fourth line therapy. FOLFOXIRI should be considered as an alternative option in patients who have received standard treatments with good performance status. Keywords: Colorectal cancer, FOLFOXIRI, Metastatic, Chemorefractory |
| first_indexed | 2024-04-10T14:24:12Z |
| format | Article |
| id | doaj.art-99ee47e43cb14facb54811693dde1939 |
| institution | Directory Open Access Journal |
| issn | 2452-3364 |
| language | English |
| last_indexed | 2024-04-10T14:24:12Z |
| publishDate | 2018-04-01 |
| publisher | Turkiye Klinikleri |
| record_format | Article |
| series | Journal of Oncological Sciences |
| spelling | doaj.art-99ee47e43cb14facb54811693dde19392023-02-15T16:09:11ZengTurkiye KlinikleriJournal of Oncological Sciences2452-33642018-04-01416061The role of FOLFOXIRI in chemorefractory metastatic colorectal cancer patientsIbrahim Yildiz0Halil Taskaynatan1Umut Varol2Tarik Salman3Utku Oflazoglu4Yasar Yildiz5Yuksel Kucukzeybek6Ahmet Alacacioglu7Mustafa Oktay Tarhan8Acibadem University Atakent Hospital, Istanbul, TurkeyDepartment of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey; Corresponding author. Medical Oncology Clinic, Izmir Katıp Celebi University, Ataturk Training and Research Hospital, 35360 Izmir, Turkey.Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, TurkeyDepartment of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, TurkeyDepartment of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, TurkeyDepartment of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, TurkeyDepartment of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, TurkeyDepartment of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, TurkeyInstitute of Oncology, Dokuz Eylul University, Izmir, TurkeyIntroduction: The use of FOLFOXIRI (oxaliplatin, irinotecan, leucovorin, and 5-fluorouracil) as first-line therapy for metastatic colorectal cancer (mCRC) is well-established. However, there is no data about the effectiveness of this regimen in pretreated patients in the current literature. In this case report, we aim to evaluate the efficacy and benefit of FOLFOXIRI in patients who received standard regimens. Case report: 3 patients were treated with FOLFOXIRI and 1 patient received FOLFOXIRI + bevasizumab. Three patients had a partial response to FOLFOXIRI; one of these patients showed disease progression on this chemotherapy regimen and died. Progression free survival (PFS) of three patients was 5.5, 9 and 7.5 months respectively. One patient showed progression without any response to treatment. Conclusion: We observed a partial response in 3 patients who were treated with FOLFOXİRİ and their progression-free survival was more than 3 months. These patients were treated with FOLFOXİRİ as a third or fourth line therapy. FOLFOXIRI should be considered as an alternative option in patients who have received standard treatments with good performance status. Keywords: Colorectal cancer, FOLFOXIRI, Metastatic, Chemorefractoryhttp://www.sciencedirect.com/science/article/pii/S2452336417301310 |
| spellingShingle | Ibrahim Yildiz Halil Taskaynatan Umut Varol Tarik Salman Utku Oflazoglu Yasar Yildiz Yuksel Kucukzeybek Ahmet Alacacioglu Mustafa Oktay Tarhan The role of FOLFOXIRI in chemorefractory metastatic colorectal cancer patients Journal of Oncological Sciences |
| title | The role of FOLFOXIRI in chemorefractory metastatic colorectal cancer patients |
| title_full | The role of FOLFOXIRI in chemorefractory metastatic colorectal cancer patients |
| title_fullStr | The role of FOLFOXIRI in chemorefractory metastatic colorectal cancer patients |
| title_full_unstemmed | The role of FOLFOXIRI in chemorefractory metastatic colorectal cancer patients |
| title_short | The role of FOLFOXIRI in chemorefractory metastatic colorectal cancer patients |
| title_sort | role of folfoxiri in chemorefractory metastatic colorectal cancer patients |
| url | http://www.sciencedirect.com/science/article/pii/S2452336417301310 |
| work_keys_str_mv | AT ibrahimyildiz theroleoffolfoxiriinchemorefractorymetastaticcolorectalcancerpatients AT haliltaskaynatan theroleoffolfoxiriinchemorefractorymetastaticcolorectalcancerpatients AT umutvarol theroleoffolfoxiriinchemorefractorymetastaticcolorectalcancerpatients AT tariksalman theroleoffolfoxiriinchemorefractorymetastaticcolorectalcancerpatients AT utkuoflazoglu theroleoffolfoxiriinchemorefractorymetastaticcolorectalcancerpatients AT yasaryildiz theroleoffolfoxiriinchemorefractorymetastaticcolorectalcancerpatients AT yukselkucukzeybek theroleoffolfoxiriinchemorefractorymetastaticcolorectalcancerpatients AT ahmetalacacioglu theroleoffolfoxiriinchemorefractorymetastaticcolorectalcancerpatients AT mustafaoktaytarhan theroleoffolfoxiriinchemorefractorymetastaticcolorectalcancerpatients AT ibrahimyildiz roleoffolfoxiriinchemorefractorymetastaticcolorectalcancerpatients AT haliltaskaynatan roleoffolfoxiriinchemorefractorymetastaticcolorectalcancerpatients AT umutvarol roleoffolfoxiriinchemorefractorymetastaticcolorectalcancerpatients AT tariksalman roleoffolfoxiriinchemorefractorymetastaticcolorectalcancerpatients AT utkuoflazoglu roleoffolfoxiriinchemorefractorymetastaticcolorectalcancerpatients AT yasaryildiz roleoffolfoxiriinchemorefractorymetastaticcolorectalcancerpatients AT yukselkucukzeybek roleoffolfoxiriinchemorefractorymetastaticcolorectalcancerpatients AT ahmetalacacioglu roleoffolfoxiriinchemorefractorymetastaticcolorectalcancerpatients AT mustafaoktaytarhan roleoffolfoxiriinchemorefractorymetastaticcolorectalcancerpatients |